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SUMMARY
Data were collected on 6578 patients diagnosed with AIDS at 52 clinical centres in 17
European countries during an 11-year period from 1979 to 1989. The centres were divided into
four regions, North, Central, Southeast, and Southwest. Differences in the incidence of most
AIDS-defining opportunistic infections and malignancies were found. After adjusting for
known possible confounders, statistically significant differences between regions remained.
Pneumocystis carinii pneumonia (PCP) was more common in Northern Europe, Kaposi’s
sarcoma and toxoplasmosis in Central Europe, cytomegalovirus retinitis in South-eastern
Europe, and extrapulmonary tuberculosis in South-western Europe. These differences we
attribute primarily to different degrees of exposure to the respective underlying pathogens. The
prevalence of these and other micro-organisms will determine the clinical course of HIV
infections in parts of Eastern Europe and elsewhere where the virus now is spreading.
INTRODUCTION
The damage caused by the human immunodeficiency
virus (HIV) gives varied clinical presentations in
different individuals. Properties of the virus [1] as well
as the immune system response [2] may influence the
course of HIV infection. Host factors may be genetic
[3] or acquired [4]. As the clinical symptoms of an
* Author for correspondence.
 Participants of the AIDS in Europe Study Group listed in
appendix.
AIDS-defining event (ADE) are caused by oppor-
tunistic infections secondary to the damaged immune
system, a necessary prerequisite is that the individual
has also been infected with the specific opportunistic
pathogen. These pathogens and therefore, also the
clinical course of an HIV infection, vary between
different geographical localities. For example, Peni-
cillum marneffei is a common opportunistic infection
in Thailand [5], Cryptococcal meningitis and crypto-
sporoidosis in parts of Africa [6, 7], and histo-
plasmosis in parts of America [8]. Mycobacterium
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tuberculosis is becoming an increasing problem where
this micro-organism is widespread in the population
[9, 10]. Findings of Mycobacterium aium complex
(MAC) infections have also been shown to vary
between different regions [11].
Besides geographical factors, life style determines
the risk for certain infections. For instance, the
Human herpes virus 8 (HHV-8), linked to the
development of Kaposi’s sarcoma (KS) [12], is more
commonly found among homosexual men than in
other transmission categories. Apart from KS only
minor gender differences in the occurrence of op-
portunistic infections have been described [13].
Following the introduction of highly active anti-
retroviral therapy (HAART) in 1996 there has been a
rapid fall in disease progression and manifestations of
AIDS among Western patients with access to treat-
ment [14, 15]. For the overwhelming majority of
patients in the world, and also for a substantial
number of patients in economically less developed
regions of Europe these drug combinations are not
available. The natural history of HIV}AIDS as it
presented before HAART could therefore be the
clinical reality for many patients and physicians. The
aim of this study was, therefore, to investigate regional
differences in the clinical consequences of an HIV
infection within Europe, using data collected on cases
of AIDS during 1979–89. The results can be of
particular guidance in health care settings which,
today, are also faced with patients with severe
immunodeficiency.
PATIENTS AND METHODS
Patients
In the ‘AIDS in Europe’ study [16] information was
collected on 6578 patients who had been diagnosed
with AIDS at 52 clinical centres in 17 European
countries (see Appendix) during an 11-year period
from 1 January 1979 to 31 December 1989. Details of
the study have been published elsewhere [16]. In short,
between May 1991 and August 1992, information was
collected from patients charts on demography, serol-
ogy, CD4 count at date of AIDS diagnosis, zidovudine
treatment (the only specific HIV therapy available at
the time) as well as diagnoses of opportunistic
infections and neoplasms. A standardized data col-
lection form was used. Members of the co-ordinating
centre visited the participating centres to ensure that
data were correctly transferred from the charts. Of
6655 patients included in the study, 77 patients were
subsequently excluded because of not fulfilling in-
clusion criteria or insufficient available information.
The revised Centers for Disease Control definition for
AIDS of 1987 was used [17].
The participating centres were divided by two latitu-
dinal lines into regions ‘north’ (Denmark, Ireland,
Finland, northern Germany, The Netherlands,
Sweden and United Kingdom), ‘central ’ (Belgium,
France, southern Germany, Hungary, Luxembourg,
and Switzerland) and ‘south’. The southern region
has the highest prevalence of HIV infections in Europe
[18], and thus there was a sufficient number of cases
to allow east–west comparisons. We therefore further
divided the Southern region by a longitudinal line
into ‘Southeast ’ (Greece, Israel, and Italy) and
‘Southwest ’ (Portugal and Spain). Published data
has shown Mycobacterium tuberculosis infections to
be most common among HIV patients in south-
western Europe (Spain in particular), suggesting not
only a possible north–south, but also an east–west
difference in the clinical presentation of AIDS [16, 19].
A similar longitudinal division of north and central
regions was not possible as there were insufficient
data from the eastern parts of these regions in
this study.
Methods
Demographic characteristics within each of the four
regions were presented as median and 25th and 75th
percentiles (continuous variables), or as frequency of
all patients with available data (non-continuous
variables). For continuous variables, the Kruskal–
Wallis rank sum test was used to test differences,
whereas the v# test was applied for differences in
frequency. All P-values were two-sided, and P! 0–05
was considered statistically significant.
Initial AIDS-defining events (ADE) included index
diagnosis(es) and the ADE(s) which were diagnosed a
month or less after the index diagnosis(es). Per-
centages of patients with specific ADEs within each
region were assessed.
We next calculated the incidence of each subsequent
AIDS-defining illness after the initial ADE, using time
from the initial ADE to the specific ADE, date of last
visit or date of death. Thus, we did not exclude
patients if they experienced other ADEs. Further-
more, patients with a specific initial ADE were not
included in the assessment of the incidence of this
ADE. The AIDS in Europe study has no data on
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recurrences of disease. Thus, only the initial episode of
each diagnosis was considered, both overall and after
stratification for region of Europe. In addition,
patients who died within a month of their initial
diagnosis were excluded. Confidence intervals (95%
CI) were calculated using a normal approximation, or
when appropriate (! 20 cases) a Poisson distribution,
and differences between regions were assessed by
Poisson regression. Regional differences in the in-
cidences of the six most common ADEs (initial as well
as subsequent ADEs) were further analysed in a Cox
proportional hazards model. The time parameter
used was the same as the one used in the incid-
ence assessment. For each of these ADEs, a model
was established and included the following baseline
parameters : age at diagnosis (! 29, 30–39, and
" 40 years), year of AIDS diagnosis (! 1987, 1987,
" 1987), gender, transmission category (homosexual,
intravenous drug use, other, and unknown), zido-
vudine treatment at baseline (yes}no), initial ADEs
(each ADE was classified according to severity [20]).
The year 1987 was chosen as the temporal dividing
line as this was the year when antiretroviral therapy
(principally zidovudine) was first available. For PCP,
the analysis was restricted to 5024 patients for whom
data on the use of PCP prophylaxis was available. In
addition, the Cox models were repeated including the
CD4 cell count for the subgroup of 3045 patients for
whom the CD4 cell count at diagnosis of AIDS was
known.
RESULTS
Table 1 describes the demographic characteristics of
patients from the four regions. Transmission through
homosexual contact dominated in Northern Europe
whilst intravenous drug use was the most common
mode of transmission in Southern Europe. Patients
were also older at diagnosis of AIDS in Northern
Europe. In the South-east, patients had developed a
more pronounced immunodeficiency when diagnosed
with AIDS. Treatment with zidovudine was less
common at time of AIDS diagnosis in the Southwest.
Table 2 presents data on the frequency of the initial
ADEs within each region. Only conditions with a
total of 40 or more cases are presented. Significant
regional differences were found for all the 15 most
common conditions except malignant lymphoma. In
the Northern and Central regions Kaposi’s sarcoma
was more common than in other regions. In the
Northern region PCP was the dominant AIDS-
defining condition whilst toxoplasmosis was more
common in the Central region. Oesophageal candi-
diasis was particularly common in the Southeast
region whilst extrapulmonary tuberculosis showed
exceptionally high figures in the Southwest region.
MAC, on the other hand, was more common in the
North and Central regions.
Median CD4 cell counts at time of AIDS for the
more common ADEs were compared between regions.
In the Southwest CD4 counts were not available in
sufficient numbers to make estimates reliable. Most
conditions were diagnosed at very similar CD4 counts
in different regions except AIDS dementia complex
which was diagnosed at higher CD4 counts in the
Central region, especially compared to the Southeast
(Pfl 0–003). KS was diagnosed at somewhat higher
CD4 counts in the central region compared especially
to the Southeast (Pfl 0–05) whilst malignant lym-
phoma was diagnosed at higher CD4 counts in the
north especially compared to the Central region (Pfl
0–04).
Table 3 presents the incidence of the 15 most
common ADEs occurring after an initial diagnosis of
AIDS. There were statistically significant differences
between regions for most of the ADEs presented and
the trends seen in Table 2 are repeated. The Northern
region had the highest incidence of PCP, KS, CMV
retinitis, MAC, cryptosporidiosis and malignant lym-
phoma. The Central region instead had the highest
incidence of toxoplasmosis whilst the Southwest has
the highest incidence of extrapulmonary tuberculosis.
In Table 4, Cox analyses of the effect of region on
risk for developing the six overall most common
ADEs are presented. When adjusting for differences
in baseline characteristics (gender, transmission
category, age at AIDS, calendar year of AIDS, and
zidovudine treatment) statistically significant dif-
ferences in the risk of developing a given ADE
remained for most diagnoses (oesophageal candidiasis
being the exception). In the Central region KS was
more commonly seen compared to the other regions.
Together with the Southwest toxoplasmosis was also
more common in the Central region. In the Southeast
CMV retinitis was diagnosed more frequently com-
pared especially to the Southwest. Finally patients in
the Southwest had a marked increased risk for
developing extrapulmonary tuberculosis. This risk
was also higher in the Southeast and Central regions
compared to the North.
The results of the Cox models remained unchanged
when repeating the analysis including CD4 cell counts
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Table 1. Demographic data for patients included in the AIDS in Europe study
All centres
(nfl 6546)
North
(nfl 2510)
Central
(nfl 1932)
Southeast
(nfl 1095)
Southwest
(nfl 1009) P-value
Gender (% female) 8–8 2–0 14–1 16–3 7–3 ! 0–001
Transmission category (%) ! 0–001
Homo-}bisexual 60–5 87–7 60–0 24–2 33–2
IVD 27–1 4–4 18–5 65–7 58–3
Other 10–3 6–0 19–1 8–9 6–0
Not known 2–1 1–9 2–4 1–3 2–6
Median age(25–75%) 34 (28–41) 37 (31–43) 34 (29–42) 29 (26–35) 30 (26–36) ! 0–001
Available CD4 cell count (%) 46–5 35–9 70–0 79–2 0 ! 0–001
(nfl 3045)
Median CD4 cell count 84 (31–198) 90 (30–200) 90 (33–216) 78 (32–174) — ! 0–05
(cells}mm$, 25–75%)
Median year of AIDS 1988 1987 1988 1988 1988 ! 0–001
diagnosis (25–75%) (1987–9) (1986–8) (1986–9) (1987–9) (1987–9)
Zidovudine treatment at time
of AIDS diagnosis (%)
7–5 6–7 9–8 10–4 1–9 ! 0–001
Table 2. First AIDS-defining eent in respectie region. Conditions with at least 40 cases presented
AIDS defining
event*
All centres North Central Southeast Southwest
P-value(nfl 6546) % (nfl 2510) % (nfl 1932) % (nfl 1095) % (nfl 1009) %
PCP 2517 38–5 1250 49–8 688 35–6 336 30–7 243 24–1 ! 0–001
Kaposi’s sarcoma 1394 21–3 680 27–1 488 25–3 113 10–3 113 11–2 ! 0–001
Oesophageal 1212 18–5 395 15–7 330 17–1 289 26–4 198 19–6 ! 0–001
candidiasis
Extrapulmonary 571 8–7 50 2–0 115 6–0 51 4–7 355 35–2 ! 0–001
tuberculosis
Toxoplasmosis 512 7–8 109 4–3 216 11–2 96 8–8 91 9–0 ! 0–001
HIV wasting 328 5–0 100 4–0 62 3–2 79 7–2 87 8–6 ! 0–001
AIDS dementia 295 4–5 3–2 110 5–7 96 8–7 9 0–9 ! 0–001
complex
Malignant 228 3–5 89 3–6 57 3–0 49 4–5 33 3–3 0–17
lymphoma
Cryptosporidosis 216 3–3 85 3–4 79 4–1 16 1–5 36 3–6 ! 0–001
Herpes simplex 199 3–0 44 1–8 111 5–8 26 2–4 18 1–8 ! 0–001
ulcer
Cryptococcosis 158 4 41 1–6 33 1–7 54 4–9 30 3–0 ! 0–001
CMV retinitis 154 2–5 57 2–3 28 1–5 44 4–0 25 2–5 ! 0–001
Mycobacterium 104 1–6 47 1–9 48 2–5 5 0–5 4 0–4 ! 0–001
aium complex
Salmonellosis 70 1–1 12 0–5 22 1–1 13 1–2 23 2–3 ! 0–001
PML 47 0–7 14 0–6 10 0–5 17 1–6 6 0–6 0–005
* PCP, Pneumocystis carinii pneumonia; PML, progressive multifocal leucoencephalopathy.
among the subset of patients with such data available
(data not given).
DISCUSSION
The study showed a pronounced difference in the
occurrence of different ADEs between different
regions of Europe, with respect to initial ADEs as well
as subsequent ADEs. Most striking was the increased
risk for extrapulmonary tuberculosis in South-western
Europe whilst toxoplasmosis and KS was more
common in Central Europe. Other regional differences
were also found.
There could be many reasons for regional dif-
147Regional presentation of AIDS in Europe
Table 3. Incidence of new AIDS-defining eents after initial diagnosis of AIDS in respectie region
AIDS defining
event*
All centres
(nfl 6546)
North
(nfl 2510)
Central
(nfl 1903)
Southeast
(nfl 1124)
Southwest
(nfl 1009) P-value
PCP 18–9 (17–6–20–3) 20–9 (18–5–23–3) 18–4 (16–2–20–6) 17–6 (14–0–21–1) 16–8 (13–6–20–0) 0–03
Oesophageal 11–6 (10–7–12–4) 11–5 (10–1–12–8) 12–2 (10–6–13–7) 12–7 (9–8–15–6) 9–1 (6–8–11–4) 0–36
candidiasis
Kaposi’s 10–3 (9–4–11–2) 14–0 (12–3–15–6) 11–5 (9–8–13–2) 4–5 (3–0–6–0) 3–3 (2–0–4–6) ! 0–0001
sarcoma
CMV retinitis 9–4 (8–6–10–1) 11–3 (10–1–12–5) 8–2 (7–0–9–4) 10–5 (8–3–12–8) 4–3 (2–9–5–8) ! 0–0001
Toxoplasmosis 7–8 (7–1–8–4) 5–8 (4–9–6–6) 10–5 (9–1–11–9) 6–3 (4–5–8–1) 9–6 (7–4–11–8) 0–001
AIDS dementia
complex
5–7 (5–2–6–3) 5–3 (4–5–6–1) 5–8 (4–8–6–7) 12–7 (10–1–15–2) 1–0 (0–3–1–6) 0–57
Mycobacterium
aium complex
4–1 (3–7–4–6) 7–1 (6–1–8–0) 2–9 (2–2–3–6) 0–5 (0–0–0–9) 0–6 (0–1–1–1) ! 0–0001
Crypto- 3–0 (2–6–3–4) 3–9 (3–2–4–5) 2–7 (2–0–3–3) 1–2 (0–4–1–9) 3–0 (1–8–4–2) 0–003
sporidosis
Malignant 2–4 (2–1–2–8) 3–3 (2–7–4–0) 1–6 (1–1–2–1) 1–9 (1–0–2–9) 1–6 (0–8–2–6) 0–0004
lymphoma
Herpes 2–4 (2–0–2–7) 1–9 (1–4–2–4) 4–0 (3–2–4–8) 1–4 (0–6–2–3) 0–7 (0–1–1–3) 0–11
simplex ulcer
Crypto- 2–1 (1–7–2–4) 2–2 (1–7–2–7) 1–2 (0–8–1–6) 2–9 (1–8–4–1) 3–5 (2–2–4–7) 0–04
coccosis
HIV wasting 1–9 (1–6–2–2) 2–3 (1–8–2–8) 0–6 (0–3–0–9) 4–2 (2–8–5–6) 1–7 (0–8–2–6) 0–81
Extra- 1–9 (1–5–2–2) 0–7 (0–4–1–0) 2–0 (1–4–2–6) 2–5 (1–4–3–6) 7–8 (5–3–10–4) ! 0–0001
pulmonary
tuberculosis
PML 0–8 (0–6–1–0) 0–7 (0–4–1–0) 1–0 (0–6–1–4) 1–1 (0–4–1–7) 0–2 (0–0–0–6) 0–63
Salmonellosis 0–7 (0–5–0–9) 0–3 (0–1–0–5) 0–7 (0–3–1–0) 1–1 (0–4–1–8) 2–3 (1–3–3–4) ! 0–0001
PCP, Pneumocystis carinii pneumonia; PML, Progressive multifocal leucoencephalopathy.
ferences in the opportunistic infections seen in HIV
infections. For example, in addition to biological
factors there may be differences in diagnostic pro-
cedures. In the North and Central regions, PCP was
the dominating initial ADE. This may be due to
diagnostic procedures [21] or a difference in the
background prevalence of the micro-organism, as
shown in other geographic localities [22]. The fact that
the condition in different European regions was
diagnosed at very similar CD4 counts makes dif-
ferences in diagnostic procedures an unlikely ex-
planation. When multivariate analysis was performed
(Table 4), this difference between regions remained.
Primary prophylaxis against PCP was introduced in
the last years of the 1980s and was taken into account
in the analysis. As year of diagnosis was included in
the analysis any temporal changes up to 1989 should
not influence the results [21]. A true regional difference
in the general prevalence of Pneumocystis carinii was
thus probable [22].
The Central region had the highest proportion of
toxoplasmosis which also remained after controlling
for known possible confounders (Table 4). This
corresponds to findings of higher sero-prevalence of
antibodies against Toxoplasma gondii in the general
population in central Europe, with the highest figures
found in France [26]. More exposure to raw meat has
been one explanation. Reactivation of latent infection
naturally becomes a problem when the infection is
widespread. Little is known about the natural preva-
lence of toxoplasma in those parts of Eastern Europe
where the prevalence of HIV now is increasing.
In the North and Central regions KS was more
common as initial ADEs and accounted for a quarter
of the cases (Table 2). This is in contrast to findings in
the general non-HIV infected population where KS is
more prevalent in Southern Europe [23]. One ex-
planation for the relatively high occurrence of KS
among HIV-infected homosexuals is that a trans-
missible causative agent was also spread within the
group [24]. The decline in the epidemic curve for this
condition supports the interpretation that men in-
fected through sex with other men were to a larger
extent also exposed to HHV-8 [12, 25]. This exposure
may also have been more pronounced in the Central
region. Taking into account regional demographic
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Table 4. Cox models for regional differences in AIDS-defining eents
Relative risk (95% confidence intervals)
Region* RR
Unadjusted
95% CI P-value RR
Adjusted
95% CI P-value
Pneumocystis N 1 — 1 —
carinii C 0–89 0–75–1–05 0–15 0–77 0–65–0–92 0–004
pneumonia SE 0–77 0–61–0–97 0–03 0–81 0–62–1–07 0–14
SW 0–76 0–61–0–95 0–02 0–78 0–50–1–21 0–26
Kaposi’s N 1 — 1 —
sarcoma C 0–83 0–68–0–99 0–04 1–28 1–06–1–54 0–01
SE 0–31 0–22–0–44 ! 0–0001 1–05 0–72–1–53 0–79
SW 0–23 0–15–0–35 ! 0–0001 0–67 0–43–1–04 0–07
CMV N 1 — 1 —
retinitis C 0–74 0–62–0–88 0–0008 0–84 0–69–1–00 0–053
SE 0–97 0–77–1–24 0–83 1–46 1–11–1–91 0–007
SW 0–39 0–27–0–55 ! 0–0001 0–58 0–40–0–84 0–004
Oesophageal N 1 — 1 —
candidiasis C 1–07 0–90–1–27 0–45 1–08 0–90–1–29 0–40
SE 1–06 0–82–1–37 0–64 1–12 0–84–1–50 0–45
SW 0–78 0–59–1–03 0–08 0–83 0–61–1–14 0–24
Extrapulmonary N 1 — 1 —
tuberculosis C 2–69 1–63–4–45 ! 0–0001 8–00 1–77–5–11 ! 0–0001
SE 3–35 1–83–6–12 ! 0–0001 3–39 1–72–6–69 0–0004
SW 10–44 6–17–17–67 ! 0–0001 11–37 6–31–20–49 ! 0–0001
Toxoplasmosis N 1 — 1 —
C 1–83 1–50–2–23 ! 0–0001 1–83 1–49–2–25 ! 0–0001
SE 1–04 0–76–1–43 0–79 1–10 0–77–1–56 0–60
SW 1–61 1–22–2–12 0–0007 1–81 1–33–2–46 ! 0–0001
* N, North; C, Central ; SE, Southeast ; SW, Southwest.
 Adjusted analysis restricted to 5024 patients with available data on PCP-prophylaxis.
differences, the higher proportion of HIV transmitted
between men in the North and Central regions as well
as younger age, and a larger proportion of trans-
mission through needle-sharing in the Southeast and
Southwest, a true regional difference in the occurrence
of KS in the HIV-positive population remained (Table
4). HHV-8 can thus be expected to have spread to a
larger degree in Central Europe.
In the Southeast region, oesophageal candidiasis
was particularly important as an initial ADE, second
only to PCP. Candida albicans is widespread world-
wide and if there are no competing opportunistic
infections this may become the AIDS-defining con-
dition. This condition is diagnosed without soph-
isticated laboratory resources. It was however diag-
nosed at similar levels of immunodeficiency in each
region suggesting usage of diagnostic procedures with
the same degree of sensitivity. If events after initial
ADE are included (Table 4) the regional differences
disappear making candida a major problem in all
regions for the immunodeficient population.
The Southwest is the only region where PCP was
not the most common ADE. Instead extrapulmonary
tuberculosis was the leading ADE both as initial
diagnosis and as subsequent infections. The obvious
explanation for this finding is, of course, that HIV
patients in this region, to a higher degree, are, or
become, infected with Mycobacterium tuberculosis.
These regional differences remain strong also in the
Cox model (Table 4). The difference can thus not be
explained by a large proportion of intravenous drug
abusers. Instead a true geographical difference exists.
As opposed to extrapulmonary tuberculosis, MAC
was less common in the Southwest and instead found
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especially in the North and Central regions. Di-
agnostic routines may vary. Also, little is known
about variations in the distribution of mycobacterium
of different strains in the environment.
CMV retinitis is uncommon as an initial ADE but
more common during the follow-up period. The
condition was more common in the Southeast after
adjustment for known possible confounders. No
obvious explanation for this difference was found. If
patients die before developing a severe fall in CD4
counts, this would, of course, lower the incidence.
Lymphomas were diagnosed more often in the
Northern region. A possible explanation could be
differences in diagnostic procedures [27]. It was
diagnosed in the North at higher CD4 counts implying
higher awareness or more aggressive investigations for
the condition. By contrast, AIDS dementia complex
was more common and diagnosed at higher CD4
counts in the Central region. One possible explanation
for this discrepancy could be differences in diagnostic
procedures and classification, whereby patients in the
North were diagnosed as non-Hodgkin’s lymphoma
and were classified as AIDS dementia complex in
Central Europe.
Some general considerations need to be made when
interpreting the data. When comparing the distri-
bution of ADEs it is necessary to keep in mind that
patients with an AIDS defining illness may be at an
increased risk of death or a further AIDS-defining
illness [28, 29]. Use of primary prophylaxis, although
it was little used in this study, can prevent conditions
such as PCP [30] and thus make CMV retinitis and
MAC more common as initial ADE among persons
who are aware of their HIV infection before develop-
ing AIDS.
Differences in transmission patterns in different
parts of Europe can also influence age at diagnosis of
AIDS. Transmission through needle sharing often
takes place at a younger age than sexual transmission.
Thus in regions with a high proportion of drug
abusers this may explain the lower age at AIDS. KS
predominantly affects homosexual men and is there-
fore more common where this mode of transmission
dominates. The Cox models controlled for such
factors in order to see what differences in ADEs can
be attributed to geographical region, after adjustment
for such confounding variables.
Treatment of opportunistic infections has improved
during the years. Survival in southern Europe was
initially shorter in the epidemic [16], limiting the
possibility of ADEs associated with advanced HIV-
infection. In spite of this, and possible inadequate
diagnostic procedures, MAC, PML, CMV retinitis
and non-Hodgkin lymphoma account for 7–11% of
initial ADEs. Few patients in the study (7–5%) had
zidovudine treatment before initial ADE. However,
zidovudine treatment cannot be expected to have had
a major impact as zidovudine monotherapy can only
be expected to postpone disease progression [31–35].
In summary, differences in populations affected by
HIV and transmission categories influence the type of
ADEs in different parts of Europe. Adjusting for the
known possible confounders, true regional differences
remain for developing PCP, toxoplasmosis, CMV
retinitis, KS and extrapulmonary tuberculosis. These
differences we attribute primarily to variations in
degree of exposure to respective pathogens. The
prevalence of these and other pathogeneses will
determine the clinical course of HIV infections in the
parts of eastern Europe and elsewhere where the virus
is now spreading.
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Schwander, Bernhard-Nocht-Institut, Hamburg; F.-
D. Goebel, Medizinische Poliklinik, Munich. Greece
(J. Kosmidls) Athens General Hospital ; G. Stergiou,
T. Gouzia, A. Papadopoulos, 1st IKA Hospital,
Athens. Hungary (D. Banhegyi) Postgraduate Medical
School, Budapest. Ireland (F. Mulcahy) St. James’s
Hospital, Dublin. Israel (I. Yust) Ichilov Hospital, Tel
Aviv; Z. Ben-Ishal, Rambam Medical Center, Haifa;
Z. Bentwich, Kaplan Hospital, Rehovot ; T. Sacks, S.
Maayan, Hadassah University Hospital, Jerusalem.
Italy (S. Vella, A. Chiesi) Istituto Superiore di Sanita,
Rome: F. Ancarani, G. Scalise, Universita’ di Ancona,
Ancona; A. Bertaggia, E. Francavilla, Osp. Civile,
Padova; G. Calonghi, Arcispedale S. Maria Nuova,
Regio Emilia ; A. Cargnel, Osp. Sacco, Milan; M.
Arlotti, R. Ciammarughi, Osp. Infermi Rimini,
Rimini ; A. Colomba, Osp. Casa del Sole, Palermo; F.
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DeLalla, Osp. Civile, Vicenza; P. Fassio, OO.RR. di
Bergami, Bergami; A. Ferlini, Osp. Infermi Faenza,
Faenza; F. Fiaccadori, G. Pasetti, Osp. Riuniti,
Parma; F. Giannelli, Osp. Niguarda ca’ Granda,
Milan; W. Grillone, Osp. Amedeo di Savoia, Turin;
A. Lazzarin, A. D’Arminio Monforte, Osp. L. Sacco,
Milan; E. Mignani, Osp. S. Andrea, La Spezia; A.
Nunnari, Patologia Medica Universita’ , Catania; L.
Ortona, Universita’ Cattolica del Sacro Cuore, Rome;
G. Panichi, Universita’ di Sassari, Sassari ; S. Pauluzzi,
Policlinico Monteluce, Perugia; N. Piersantelli, Osp.
Galliera, Genova; S. Ranieri, Osp. S. Maria delle
Croci, Ravenna; P. Ricciardiello, Osp. Maggiore,
Novara; B. Roscioli, Osp. S. Maria Maddalena,
Trieste ; M. Soranzo, Osp. Amedeo di Savoia, Turin.
Luxembourg (R. Hemmer), Centre Hospitalier,
Luxembourg. The Netherlands (S. Danner), P. Reiss,
Academisch Ziekenhuis bij de Universitet van
Amsterdam. Portugal (F. Antunes), Hospital Santa
Maria; R. Proenca, Hospital Curry Cabral, Lisbon.
Spain (J. Gonza! lez-Lahoz), P. Rosa, Instituto Carlos
III, Madrid; B. Clotet, Hospital Germans Trias i
Pujol, Badalona; J. Gatell, E. Buira, J. Miro! , Hospital
Clinic I Provincial, Barcelona. Sweden (P. Pehrson),
Karolinska Institutet, Stockholm. Switzerland (R.
Lu$ thy), B. Ledergerber, C. Olsson, Swiss HIV cohort
study, Zu$ rich; M. Glauser, Centre Hospitalier Uni-
versitaire Vaudois, Lausanne; B. Hirschel, Hospital
Cantonal Universitaire de Geneve, Geneve. United
Kingdom (A. Johnson), S. Hawkes, A. Phillips, UCL
Medical School ; S. Barton, J. Morcinek, St. Stephen’s
Clinic, Chelsea and Westminster Hospital ; A.
Pinching, D. Coleman, St. Mary’s Hospital, London.
Coordinating centre staff : I. Gjørup, J. Lundgren, J.
Nielsen, C. Nieport, C. Pedersen, L. Teglbjaerg, A.
Thornval.
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